FrancophonIA/ELRC3.0 huggingface dataset:
English: - neutropenia in patients with HIV infection, - peripheral blood stem cell mobilisation.
Estonian: Filgrastim ratiopharm´i kasutatakse järgmiste haiguste puhul: - keemiaravi - luuüdi siirdamine - neutropeenia HIV-nakkusega patsientidel - tüvirakkude mobiliseerumine perifeersesse verre
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Filgrastim ratiopharm 48 MIU/0.8 ml solution for injection or infusion
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE Filgrastim ratiopharm 48 MIU/0,8 ml süste- või infusioonilahus Filgrastiim
English: Reversible, dose-dependent and usually mild or moderate elevations of lactate dehydrogenase (LDH), alkaline phosphatase, serum uric acid and gamma-glutamyltransferase (GGT) occurred with filgrastim in approximately 50%, 35%, 25%, and 10% of patients respectively, at recommended doses.
Estonian: Filgrastiimi soovitatud annuste manustamisel on kirjeldatud pöörduvat, annusest sõltuvat ja enamasti kerget või mõõdukat laktaatdehüdrogenaasi (LDH) aktiivsuse, alkaalse fosfataasi aktiivsuse, seerumi kusihappesisalduse ja gammaglutamüültranspeptidaasi (GGT) aktiivsuse suurenemist.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Carton
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp
English: Your doctor will monitor your blood to determine the best time to
Estonian: Arst teeb teile vereanalüüsi, et kindlaks määrata, millal on sobivaim aeg tüvirakkude kogumiseks.
English: Malta ratiopharm GmbH, Il Ġermanja
Estonian: Merckle Biotec GmbH Dornierstraße 10
English: However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte
Estonian: MDS-i või leukeemia ilmnemisel tuleb ravi filgrastiimiga katkestada.
English: Anaemia and epistaxis have also been
Estonian: Kirjeldatud on ka aneemia ja ninaverejooksu juhtumeid.
English: Thrombocytopenia
Estonian: Ninaverejooks
English: In addition, an updated RMP should be submitted
Estonian: Lisaks tuleb riski haldamis plaani teostada:
English: 0.65 ml (200 µg/ml) 4 pre-filled pens
Estonian: 4 viaais
English: • schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
Estonian: • Skisofreenia - vaimuhaigus, millel on mitmesuguseid sümptomeid, sealhulgas mõtlemis- ja kõnehäired, hallutsinatsioonid (ebareaalsete asjade kuulmine või nägemine), kahtlustamine ja luulud.
English: The full EPAR and risk management plan summary for Aripiprazole Mylan Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Aripiprazole Mylan Pharmai kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The name of the medicine was changed to Aripiprazole Mylan Pharma on 3 June 2016.
Estonian: Ravimi nimetus muudeti 3. juunil 2016 Aripiprazole Mylan Pharmai.
English: A risk management plan has been developed to ensure that Aripiprazole Mylan Pharma is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Aripiprazole Mylan Pharmai võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aripiprazole Pharmathen on 30 June 2015.
Estonian: Euroopa Komisjon andis Aripiprazole Pharmatheni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. juunil 2015.
English: The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Mylan Pharma is broken down in the body.
Estonian: Annust tuleb kohandada patsientidel, kes võtavad teisi ravimeid, mis mõjutavad Aripiprazole Mylan Pharmai lagunemist organismis.
English: What measures are being taken to ensure the safe and effective use of Aripiprazole Mylan Pharma?
Estonian: Mis meetmed võetakse, et tagada Aripiprazole Mylan Pharmai ohutu ja efektiivne kasutamine?
English: The Committee recommended that Aripiprazole Mylan Pharma be approved for use in the EU.
Estonian: Komitee soovitas Aripiprazole Mylan Pharmai kasutamise Euroopa Liidus heaks kiita.
English: Aripiprazole Mylan Pharma is available as tablets (5, 10, 15 and 30 mg) and can only be obtained with a prescription.
Estonian: Aripiprazole Mylan Pharmai turustatakse tablettidena (5, 10, 15 ja 30 mg).
English: Because Aripiprazole Mylan Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Aripiprazole Mylan Pharma on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Aripiprazole Mylan Pharma.
Estonian: See on ravimi Aripiprazole Mylan Pharma Euroopa avaliku hindamisaruande kokkuvõte.
English: In addition, the company that markets Aripiprazole Mylan Pharma will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in patients between 13 and 17 years.
Estonian: Aripiprazole Mylan Pharmai tootja varustab ka patsiendid, nende hooldajad ja arstid teabepakmega, mis selgitab ravimi ohutut kasutamist 13-17-aastastel patsientidel.
English: Aripiprazole Mylan Pharma is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past.
Estonian: Aripiprazole Mylan Pharmai kasutatakse mõõdukate ja raskete maaniaepisoodide raviks täiskasvanutel ja uute maaniaepisoodide ennetamiseks täiskasvanutel, kellel on varem tekkinud sellele ravimile ravivastus.
English: What is Aripiprazole Mylan Pharma and what is it used for?
Estonian: Mis on Aripiprazole Mylan Pharma ja milleks seda kasutatakse?
English: This means that Aripiprazole Mylan Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Abilify.
Estonian: See tähendab, et Aripiprazole Mylan Pharma on sarnane võrdlusravimiga Abilify, millel juba on Euroopa Liidus müügiluba.
English: Aripiprazole Mylan Pharma is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Estonian: Aripiprazole Mylan Pharmai kasutatakse ka kuni 12 nädalat kestvaks mõõdukate ja raskete maaniaepisoodide raviks vähemalt 13-aastastel patsientidel.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Abilify.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Aripiprazole Mylan Pharma võrreldav kvaliteet ja bioekvivalentsus ravimiga Abilify.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Mylan Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Aripiprazole Mylan Pharmai omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For practical information about using Aripiprazole Mylan Pharma, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Aripiprazole Mylan Pharmai kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For treating manic episodes in bipolar disorder, the recommended starting dose in adults is 15 mg by mouth once a day, either on its own or in combination with other medicines.
Estonian: Bipolaarse meeleoluhäirega kaasnevate maaniaepisoodide korral on täiskasvanute soovitatav algannus suukaudsel manustamisel 15 mg üks kord ööpäevas ainsa ravimina või kombinatsioonis teiste ravimitega.
English: Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine'.
Estonian: Aripiprazole Mylan Pharma sisaldab toimeainena aripiprasooli ja on geneeriline ravim.
English: Other information about Aripiprazole Mylan Pharma
Estonian: Muu teave Aripiprazole Mylan Pharmai kohta
English: For more information about treatment with Aripiprazole Mylan Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Aripiprazole Mylan Pharmaiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Aripiprazole Mylan Pharma is used in patients with the following mental illnesses:
Estonian: Aripiprazole Mylan Pharmai kasutatakse järgmiste vaimuhaigustega patsientide raviks.
English: It is not intended to provide practical advice on how to use Aripiprazole Mylan Pharma.
Estonian: Hindamisaruandes ei anta Aripiprazole Mylan Pharmai kasutamise praktilisi nõuandeid.
English: For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day.
Estonian: Maaniaepisoodide ravi algannus 13-17-aastastel patsientidel on 2 mg ööpäevas (kasutatakse vedelikuna turustatavat aripiprasooli ravimpreparaati), mida suurendatakse järk-järgult kuni soovitusliku annuseni 10 mg üks kord ööpäevas.
English: Why is Aripiprazole Mylan Pharma approved?
Estonian: Miks Aripiprazole Mylan Pharma heaks kiideti?
English: Because Aripiprazole Mylan Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify.
Estonian: Et Aripiprazole Mylan Pharma on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Aripiprazole Mylan Pharmai bioekvivalentsust võrdlusravimiga Abilify.
English: Aripiprazole Mylan Pharma is used in patients aged 15 years or over;
Estonian: Aripiprazole Mylan Pharmai kasutatakse vähemalt 15-aastastel patsientidel.
English: Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Abilify korral, ületab ravimi Aripiprazole Mylan Pharma kasulikkus sellega kaasnevad riskid.
English: The active substance in Aripiprazole Mylan Pharma, aripiprazole, is an antipsychotic medicine.
Estonian: Aripiprazole Mylan Pharmai toimeaine aripiprasool on antipsühhootikum.
English: Aripiprazole Mylan Pharma aripiprazole
Estonian: Aripiprazole Mylan Pharma1
English: Previously known as Aripiprazole Pharmathen.
Estonian: Varasem nimetus Aripiprazole Pharmathen.
English: How does Aripiprazole Mylan Pharma work?
Estonian: Kuidas Aripiprazole Mylan Pharma toimib?
English: How is Aripiprazole Mylan Pharma used?
Estonian: Kuidas Aripiprazole Mylan Pharmai kasutatakse?
English: How has Aripiprazole Mylan Pharma been studied?
Estonian: Kuidas Aripiprazole Mylan Pharmai uuriti?
English: What are the benefits and risks of Aripiprazole Mylan Pharma?
Estonian: Milles seisneb Aripiprazole Mylan Pharmai kasulikkus ja mis riskid ravimiga kaasnevad?
English: 17170 Amer SPAIN
Estonian: 17170 Amer HISPAANIA
English: No specific risk to animal health was identified.
Estonian: Spetsiifilisi riske loomatervisele ei ole tuvastatud.
English: The Committee was also asked to recommend whether the marketing authorisations should be maintained, varied, suspended or withdrawn.
Estonian: Samuti paluti veterinaarravimite komitee soovitust, kas ravimite müügiload tuleb säilitada, muuta, peatada või tühistada.
English: Grounds for maintaining the marketing authorisations
Estonian: Müügilubade säilitamise alused
English: A. et al,.
Estonian: Lurrete, A. et al,.
English: List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, applicant/marketing authorisation holders in the Member States
Estonian: Veterinaarravimite nimetuste, ravimvormide, tugevuste, loomaliikide, manustamisviiside ja müügiloa taotlejate/hoidjate loetelu liikmesriikides
English: Efficacy in target animals
Estonian: Efektiivsus sihtloomaliikidel
English: Unfortunately, there is insufficient information on the interpretation criteria used on the RESAPATH annual reports.
Estonian: Kahjuks ei ole piisavalt teavet RESAPATH-i aastaaruannetes kasutatud tõlgendamiskriteeriumide kohta.
English: The treatment did not affect the estimated water consumption of animals (about 100 ml/kg body weight).
Estonian: Ravi ei mõjutanud loomade hinnangulist veetarbimist (u 100 ml/kg).
English: Of the strains examined, 86.67% were susceptible to enrofloxacin, 10% were intermediate and 3.33% were resistant.
Estonian: Uuritud tüvedest olid 86,67% enrofloksatsiini suhtes tundlikud, 10% tüvede tundlikkus oli vahepealne ja 3,33% tüvedest olid resistentsed.
English: Resistance transmission has not been studied specifically in rabbits.
Estonian: Resistentsuse ülekandumist küülikutel ei ole eraldi uuritud.
English: Gran Via Carlos III 98 - 7ª 08028 Barcelona SPAIN
Estonian: Gran Via Carlos III 98 - 7ª 08028 Barcelona HISPAANIA
English: Risk for public health
Estonian: Risk rahvatervisele
English: Fluoroquinolones have been authorised for use in these species for many years.
Estonian: Fluorokinoloonide kasutamine nendel loomaliikidel on heaks kiidetud juba aastaid.
English: 2 Petersen A, Christensen JP, Kuhnert P, Bisgaard M, Olsen JE, 2006.
Estonian: 2 Petersen, A., Christensen, J. P., Kuhnert, P., Bisgaard, M., Olsen, J. E., 2006.
English: Thus, it was possible for the animals to receive the indicated dose of antibiotic.
Estonian: Seega oli loomadel võimalik saada joogiveega eelmainitud antibiootikumiannuseid.
English: The current knowledge regarding the occurrence of antimicrobial resistance in food animals and the influence of the animal production on its transmission is incomplete.
Estonian: Praegused teadmised mikroobide resistentsuse tekke kohta toiduloomadel ja loomakasvatuse mõju kohta nende levikule on ebapiisavad.
English: A less well characterised and possibly slightly higher risk as compared to other species could be acceptable in case of a minor species.
Estonian: Vähem kirjeldatud ja võib-olla ka suurem risk on vähelevinud liikide korral vastuvõetav.
English: In addition this process seems to be immediate which means that the overall time during which faeces of rabbits are exposed to enrofloxacin during treatment is not significantly higher than without the coprophagy practice.
Estonian: Pealegi näib see mõju olevat lühiajaline, mis tähendab, et aeg, mille vältel küülikute väljaheide puutub ravi ajal kokku enrofloksatsiini toimega, ei ole oluliselt pikem, kui see oleks ilma koprofaagiata.
English: Sensitivity of various strains of P. multocida was analysed in Spain between 2009 and 2011 and the antibiogram results showed that of a total of 61 P. multocida isolates all 61 strains were sensitive.
Estonian: Aastatel 2009-2011 uuriti Hispaanias P. multocida tüvede tundlikkust ja antibiogrammi tulemuste järgi olid P. multocida 61 isolaadist kõik 61 tüve tundlikud.
English: • Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
Estonian: • Kui vähegi võimalik, kasutada veterinaarravimit vaid tundlikkuse testidele tuginedes.
English: • no additional risk management or mitigation measures nor prohibition of enrofloxacin in rabbits was considered proportionate;
Estonian: • komitee ei pidanud riskiga proportsionaalseks täiendavate riskijuhtimis- või riskileevendamismeetmete võtmist ega enrofloksatsiini kasutamise keelamist küülikutel;
English: Several MIC data on P. multocida isolated from clinical samples from 30 Spanish rabbit farms in 2006 and 2007 were provided.
Estonian: Samuti esitati MIC-andmed P. multocida tüvede kohta, mis isoleeriti Hispaania 30 küülikufarmi kliinilistest proovidest aastatel 2006 ja 2007.
English: The evaluation of the risk related antimicrobial resistance has to consider both effects; on the target animal species and in humans.
Estonian: Mikroobide resistentsuse riski hindamisel tuleb arvestada mõlema mõjuga: mõju sihtloomaliikidele ja inimestele.
English: • Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.
Estonian: • Fluorokinoloone tuleks hoida kliiniliste seisundite raviks, mis alluvad või arvatavasti alluvad halvasti ravile teiste klasside antimikroobsete preparaatidega.
English: SP VETERINARIA Ctra.Reus-Vinyols, Km, 43330 Ruidoms SPAIN
Estonian: SP VETERINARIA Ctra.Reus-Vinyols, Km, 43330 Ruidoms HISPAANIA
English: Restrictions on availability of antimicrobials for rabbits may cause animal health and welfare concerns.
Estonian: Küülikute mikroobivastase ravi piirangud võivad halvendada loomade tervist ja heaolu.
English: The prudent use recommendations and warnings that are listed in the product information for these products should be strictly followed and the products should not be used as a first line treatment.
Estonian: Nende ravimite ravimiteabes esitatud mikroobivastaste ravimite aruka kasutamise soovitusi ja hoiatusi tuleb täpselt järgida ning neid ravimeid ei tohi kasutada esmavaliku ravimitena.
English: It is very important that those antimicrobials are used in veterinary and human medicine according to responsible use principles to safeguard the efficacy of these substances and minimise the development of and dissemination of antimicrobial resistance.
Estonian: Seetõttu on äärmiselt oluline, et neid mikroobivastaseid aineid kasutataks veterinaar- ja inimmeditsiinis vastutustundliku kasutamise põhimõttel, et tagada nende ainete efektiivsus ning minimeerida mikroobide resistentsuse tekke ja selle leviku võimalus.
English: The use of fluoroquinolones in rabbits may therefore have a higher risk on development of antimicrobial resistance, however this risk is theoretical.
Estonian: Seetõttu võib fluorokinoloonide kasutamine küülikutel olla seotud mikroobide resistentsuse tekke suurema riskiga, kuigi see risk on üksnes teoreetiline.
English: This observed decrease of susceptibility could either be explained by methodological factors, or it could reflect a true emergence of decreased susceptibility, that could be related to the use of enrofloxacin in rabbits or other animal species.
Estonian: Tundlikkuse täheldatud vähenemine võib tuleneda uuringumeetodist, kuid see võib viidata ka tundlikkuse tegelikule vähenemisele, mis võib olla seotud enrofloksatsiini kasutamisega küülikutel ja teistel loomaliikidel.
English: The species for which spread of MRSA would be important is therefore mainly swine (high prevalence) and companion animals (close contact).
Estonian: Loomaliigid, kellel võiks arvestada MRSA levimisty, on eelkõige sead (suur levimus) ja lemmikloomad (lähedane kokkupuude).
English: Data on susceptibility of enrofloxacin from a study conducted in Spain in 2005 showed a MIC90 of 0.06 µg/ml.
Estonian: Enrofloksatsiini tundlikkuse uuringus, mis toimus 2005. aastal Hispaanias, saadi MIC90-väärtuseks 0,06 µg/ml.
English: The products are authorised for use in the target species chickens, turkeys and rabbits.
Estonian: Ravimite kasutamine on heaks kiidetud sihtliikidel kanadel, kalkunitel ja küülikutel.
English: With regard to intensively reared rabbits, the risk is likely to be minor in comparison with the other species due to the size of rabbits production and no measures have been deemed necessary to minimise the risk for spread of MRSA from those.
Estonian: Küülikute intensiivse kasvatuse korral on risk võrreldes teiste loomaliikidega küülikukasvatuse väikese mahu tõttu ilmselt minimaalne, mistõttu ei ole ka peetud vajalikuks võtta meetmeid, et minimeerida MRSA küülikutelt leviku riski.
English: The antimicrobial prudent use recommendations and warnings that are included in the product information are as follows:
Estonian: Ravimiteabesse lisatud mikroobivastaste ravimite aruka kasutamise soovitused ja hoiatused on järgmised:
English: France considered that these resistances would possibly be directly or indirectly transmitted to humans and may represent a potential serious risk to public health as enrofloxacin belongs to the fluoroquinolones family which is considered a highly critical class of antimicrobials for human health.
Estonian: Prantsusmaa leidis, et resistentsus võib otseselt või kaudselt levida ka inimestele ning ohustada seetõttu rahvatervist, sest enrofloksatsiin kuulub fluorokinoloonide rühma, mis on inimtervise seisukohalt suure tähtsusega mikroobivastased ravimid.
English: Rabbits are raised in continuous systems where resistant bacteria might be persistent over time, however the overall risk would remain low due to the low consumption of rabbit meat.
Estonian: Küülikuid kasvatatakse pidevate järjestikuliste põlvkondadena, kus resistentsed bakterid võivad püsida pikka aega, aga sellest tulenev üldine risk on küülikuliha vähese tarbimise tõttu väike.
English: It is anticipated that the risk on individual level might be increased for rabbit as compared to other species.
Estonian: Võib eeldada, et risk üksiklooma tasemel on küülikutel suurem kui teistel loomaliikidel.
English: • Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Estonian: • Kõrvale kaldumine preparaadi kasutamisel ravimi omaduste kokkuvõttes antud juhistest võib suurendada bakterite resistentsuse teket fluorokinoloonidele ning võib vähendada ravi efektiivsust teiste kinoloonidega potentsiaalse ristresistentsuse tõttu.
English: 08028 - BARCELONA SPAIN
Estonian: 08028 - BARCELONA HISPAANIA
English: The enrofloxacin is an antimicrobial belonging to the class of fluoroquinolones, which are listed by the WHO as a critically important class of antimicrobials for human health (Critically important antimicrobials for human medicine, WHO/AGISAR, Copenhagen, 2009).
Estonian: Enrofloksatsiin on mikroobivastane ravim, mis kuulub fluorokinoloonide klassi ja mis on WHO liigituse järgi inimtervise jaoks suure tähtsusega mikroobivastaste ravimite klass (Critically important antimicrobials for human medicine, WHO/AGISAR, Copenhagen, 2009; elutähtsate antimikroobikumide korrapärane või registreerimata näidustustel kasutamine inimtervishoius).
English: There are two risks for public health identified with the use of enrofloxacin in rabbits: (i) the risk for spread of methicillin resistant Staphylococcus aureus (MRSA) from rabbits to people in contact with these animals and (ii) the risk of spread of resistant zoonotic bacteria and transmissible resistance genes via food, e.g. Salmonella and E. coli.
Estonian: Enrofloksatsiini kasutamine küülikutel on seotud kahe tuvastatud riskiga rahvatervisele: i) risk, et metitsilliiniresistentne Staphylococcus aureus (MRSA) levib küülikutelt nendega kokkupuutuvatele inimestele, ja ii) risk, et toidu kaudu võivad levida resistentsed zoonootilised bakterid (nt Salmonella ja E. coli) ning ülekanduvad resistentsusgeenid.
English: Regarding the second risk, spread of resistant zoonotic bacteria and resistance genes via food, this is a well characterised risk for which CVMP in November 2006 recommended risk mitigation measures7.
Estonian: Teine nimetatud risk, resistentsete zoonootiliste bakterite ja resistentsust kodeerivate geenide levik toiduga, on samuti selgelt väljendunud ja selle ennetamiseks soovitas veterinaarravimite komitee novembris 2006 võtta mitu riskivähendusmeedet7.